Patent classifications
A61K8/14
Micelles and vesicles for the delivery of glycopeptides
Methods for quality control and optimizing the formation and characterization of micelles, vesicles or other aggregates are described herein. Pharmaceutically relevant peptides may be modified to form glycopeptide surfactants which form micelles or other aggregates with another surfactant. Glycopeptide and glycolipid surfactants can aggregate to form particles that enhance drug delivery. The glycopeptide surfactants may be drugs or pro-drugs which are delivered via the micelles or other aggregated structures.
DELIVERY CARRIER INTO CELL
[Problem to be Solved]
Provided is a delivery carrier into the cell having high antioxidant activity, intracellular absorbability, intracellular disintegration property, stability and safety, which have high delivery property of the active ingredient to cell and living tissues.
[Solution]
The delivery carrier into cells includes a vitamin derivative with co-activation of both autophagy-related genes and protease synthesis genes, a polymer molecule containing stimulatory reactivity, an emulsion stabilizer, an active ingredient, and a lipid, thereby providing a delivery carrier into cells with high delivery properties of the active ingredient to cells and living tissues.
DELIVERY CARRIER INTO CELL
[Problem to be Solved]
Provided is a delivery carrier into the cell having high antioxidant activity, intracellular absorbability, intracellular disintegration property, stability and safety, which have high delivery property of the active ingredient to cell and living tissues.
[Solution]
The delivery carrier into cells includes a vitamin derivative with co-activation of both autophagy-related genes and protease synthesis genes, a polymer molecule containing stimulatory reactivity, an emulsion stabilizer, an active ingredient, and a lipid, thereby providing a delivery carrier into cells with high delivery properties of the active ingredient to cells and living tissues.
Immunomodulatory composition comprising lactobacillus-derived extracellular vesicles
The present specification discloses an immunomodulatory composition comprising lactobacillus-derived extracellular vesicles as an active ingredient. The lactobacillus may be Lactobacillus plantarum. The composition has the effects of inducing differentiation into M2-type macrophages and reducing expression of at least one member selected from the group consisting of CCR2, SOCS3 and HLA-DRα, which are M1-type macrophage differentiation markers.
Immunomodulatory composition comprising lactobacillus-derived extracellular vesicles
The present specification discloses an immunomodulatory composition comprising lactobacillus-derived extracellular vesicles as an active ingredient. The lactobacillus may be Lactobacillus plantarum. The composition has the effects of inducing differentiation into M2-type macrophages and reducing expression of at least one member selected from the group consisting of CCR2, SOCS3 and HLA-DRα, which are M1-type macrophage differentiation markers.
COSMETIC COMPOSITION AND METHOD
A cosmetic composition includes one or more solvents and one or more rejuvenation cosmetic components. The one or more solvents include dimethyl sulfoxide and/or dimethyl sulfone. The one or more rejuvenation cosmetic components, include botulinum toxin, hyaluronic acid, and/or exosomes. A delivery system includes a transdermal patch including the cosmetic composition. The cosmetic composition is topically applied to the skin of a patient.
COSMETIC COMPOSITION AND METHOD
A cosmetic composition includes one or more solvents and one or more rejuvenation cosmetic components. The one or more solvents include dimethyl sulfoxide and/or dimethyl sulfone. The one or more rejuvenation cosmetic components, include botulinum toxin, hyaluronic acid, and/or exosomes. A delivery system includes a transdermal patch including the cosmetic composition. The cosmetic composition is topically applied to the skin of a patient.
Stem cell stimulating compositions and methods
The inventive subject is directed towards ready-to-use topical cosmetic formulations that include at least one defensin present in sub-antimicrobially effective concentrations. Surprisingly, even at such low concentrations, defensins recruit LGR6+ stem cells from hair follicles to the interfollicular space. Including defensins in the inventive topical cosmetic formulations may reduce one or more of wrinkle depth, wrinkle length, wrinkle width, pore size, irregularity in texture of a skin surface, oiliness, brown spots, and red spots in non-injured skin, thus reducing apparent age.
Self-emulsifiable composition, production method therefor, nanoemulsion, and production method therefor
The present invention relates to a self-emulsifiable composition including a monoacyl phospholipid, a diacyl phospholipid, oils and fats, and a polyhydric alcohol, in which the content ratio between the monoacyl phospholipid and the diacyl phospholipid is in the range of monoacyl phospholipid:diacyl phospholipid=1:9 to 9:1 as a mass ratio.
Self-emulsifiable composition, production method therefor, nanoemulsion, and production method therefor
The present invention relates to a self-emulsifiable composition including a monoacyl phospholipid, a diacyl phospholipid, oils and fats, and a polyhydric alcohol, in which the content ratio between the monoacyl phospholipid and the diacyl phospholipid is in the range of monoacyl phospholipid:diacyl phospholipid=1:9 to 9:1 as a mass ratio.